Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-604: pembrolizumab plus etoposide/platinum versus placebo plus etoposide/platinum in first-line extensive-stage small cell lung cancer
MOH_2017-03-26_000075Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Pembrolizumab plus etoposide/platinum with Placebo plus etoposide/platinum (2 arms). Started Mar 2017; status: active, not recruiting.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2017-03-26_000075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-26_000075.